date:Aug 25, 2016
ty of GRAS substances as new scientific information emerges.
In lieu of its own system, the FDA should at least be responsive to the citizen petition mechanism that allows members of the public and public interest organizations to raise safety concerns with the agency. Historically, the FDA has not actively considered citizen petitions that challenge the safety of GRAS substances, only deciding on the merits of one out of 11 petitions submitted to the agency between 2004 and 2008, according to